64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
about
Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Nanoparticle-Based Magnetic Resonance Imaging on Tumor-Associated Macrophages and Inflammation.Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.Conditioning neoadjuvant therapies for improved immunotherapy of cancer.Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.Transport of drugs from blood vessels to tumour tissue.Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.Progress and challenges towards targeted delivery of cancer therapeutics.Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment.Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines.Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast CancerMulti-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft modelsUltrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancerSelf-assembling supramolecular dendrimer nanosystem for PET imaging of tumorsImaging Nanomedicine-Based Drug Delivery: a Review of Clinical StudiesImpact of the hypoxic phenotype on the uptake and efflux of nanoparticles by human breast cancer cells
P2860
Q30354652-C1912DCC-13EF-4579-BF62-EE859BEA69BDQ33710955-11B0DFEC-E580-4C94-9FFC-0F4E79FEC725Q38645927-849EF31D-38BC-4873-96E8-F8D4BC172DAEQ45065285-4B9E4E15-4250-425C-AB15-AE55A6BDBF2CQ47118009-7BF4175D-BFE1-4001-9968-646821D22F7AQ47549277-9773601F-5F4C-46F1-83AE-874D5463F3E5Q50082408-5B1D26FD-DFE7-4BD1-89ED-9A4575463837Q50422486-1162237E-1347-4707-86CE-0A996C9C61C5Q52590993-6F13CE34-EA00-4EBA-9963-66ECEBF844E7Q52707854-83D0BD0E-77EB-44A0-88BD-0D9BBC758FA2Q55265623-18BE7DBF-A6E0-4BF9-96A4-28552723B285Q57110662-8BD57A88-3DB0-4A0D-A771-0370C920D589Q57181925-0A70944E-CD9A-48B5-9C97-A01A65DA97BDQ57295430-5D8E8D5F-1BAE-4D4B-89F4-D22ED96BBF85Q57805470-7EBF0085-A5C5-4A35-B854-D009327309B5Q58147367-7F1D7D19-9C10-4278-A54C-94EC87FDD3DEQ58771197-C94748E2-A681-4A92-8D69-83E1B7648809
P2860
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
64Cu-MM-302 Positron Emission ...... with Metastatic Breast Cancer.
@en
64Cu-MM-302 Positron Emission ...... with Metastatic Breast Cancer.
@nl
type
label
64Cu-MM-302 Positron Emission ...... with Metastatic Breast Cancer.
@en
64Cu-MM-302 Positron Emission ...... with Metastatic Breast Cancer.
@nl
prefLabel
64Cu-MM-302 Positron Emission ...... with Metastatic Breast Cancer.
@en
64Cu-MM-302 Positron Emission ...... with Metastatic Breast Cancer.
@nl
P2093
P1476
64Cu-MM-302 Positron Emission ...... with Metastatic Breast Cancer
@en
P2093
Anthony F Shields
Barry A Siegel
Bart S Hendriks
Cynthia X Ma
Daniel F Gaddy
Elena Geretti
Karen Campbell
Kathy D Miller
P304
P356
10.1158/1078-0432.CCR-16-3193
P407
P577
2017-03-15T00:00:00Z